{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:51:39Z","timestamp":1787068299420,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T00:00:00Z","timestamp":1580169600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T00:00:00Z","timestamp":1580169600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["5\/13\/58\/2014\/NCD-III"],"award-info":[{"award-number":["5\/13\/58\/2014\/NCD-III"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology , Ministry of Science and Technology","doi-asserted-by":"publisher","award":["BT\/PR13357\/MED\/30\/1532\/2015"],"award-info":[{"award-number":["BT\/PR13357\/MED\/30\/1532\/2015"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Overexpression of FAT1 gene and its oncogenic effects have been reported in several cancers. Previously, we have documented upregulation of FAT1 gene in glioblastoma (GBM) tumors which was found to increase the expression of proinflammatory markers, HIF-1\u03b1, stemness genes and EMT markers in glioma cells. Here, we reveal NF\u043aB (RelA)\/RelA\/p65 as the transcriptional regulator of FAT1 gene in GBM cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      <jats:italic>In-silico<\/jats:italic>\n                      analysis of FAT1 gene promoter was performed using online bioinformatics tool Promo alggen (Transfac 8.3) to identify putative transcription factor(s) binding motifs. A 4.0\u2009kb FAT1 promoter (\u2212\u20093220\u2009bp to +\u2009848\u2009bp w.r.t. TSS\u2009+\u20091) was cloned into promoter less pGL3Basic reporter vector. Characterization of FAT1 promoter for transcriptional regulation was performed by in-vitro functional assays using promoter deletion constructs, site directed mutagenesis and ChIP in GBM cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Expression levels of NF\u043aB (RelA) and FAT1 were found to be increased and positively correlated in GBM tumors (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200916), REMBRANDT GBM-database (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009214) and TCGA GBM-database (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009153). In addition to glioma, positive correlation between NF\u043aB (RelA) and FAT1 expression was also observed in other tumors like pancreatic, hepatocellular, lung and stomach cancers (data extracted from TCGA tumor data). A 4.0\u2009kb FAT1-promoter-construct [\u2212\u20093220\u2009bp\/+\u2009848\u2009bp, transcription start site (TSS)\u2009+\u20091, having 17 NF\u043aB (RelA) motifs] showed high FAT1 promoter luciferase-activity in GBM cells (U87MG\/A172\/U373MG). FAT1 promoter deletion-construct pGL3F1 [\u2212\u2009200\u2009bp\/+\u2009848\u2009bp, with 3-NF\u043aB (RelA)-motifs] showed the highest promoter activity. Exposure of GBM cells to known NF\u043aB (RelA)-activators [severe-hypoxia\/TNF-\u03b1\/ectopic-NF\u043aB (RelA)\u2009+\u2009IKBK vectors] led to increased pGL3F1-promoter activity and increased endogenous-FAT1 expression. Conversely, siRNA-mediated NF\u043aB (RelA) knockdown led to decreased pGL3F1-promoter activity and decreased endogenous-FAT1 expression. Deletion of NF\u043aB (RelA)-motif at \u2212\u200990\u2009bp\/\u2212\u200980\u2009bp [pGL3F1\u03b41-construct] showed significant decrease in promoter activity. Site directed mutagenesis at -90\u2009bp\/\u2212\u200980\u2009bp and ChIP assay for endogenous-NF\u043aB (RelA) confirmed the importance of this motif in FAT1 expression regulation. Significant reduction in the migration, invasion as well as colony forming capacity of the U87MG glioma cells was observed on siRNA-mediated knockdown of NF\u043aB (RelA).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Since FAT1 and NF\u043aB (RelA) are independently known to promote pro-tumorigenic inflammation and upregulate the expression of HIF-1\u03b1\/EMT\/stemness in tumors, targeting the NF\u043aB (RelA)-FAT1 axis may attenuate an important tumor-promoting pathway in GBM. This may also be applicable to other tumors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-019-6435-1","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T16:14:13Z","timestamp":1580228053000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["NF\u043aB is a critical transcriptional regulator of atypical cadherin FAT1 in glioma"],"prefix":"10.1186","volume":"20","author":[{"given":"Chitrangda","family":"Srivastava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khushboo","family":"Irshad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakhlesh","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitra","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Suri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parthaprasad","family":"Chattopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subrata","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7065-3395","authenticated-orcid":false,"given":"Kunzang","family":"Chosdol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,28]]},"reference":[{"key":"6435_CR1","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nrc2246","volume":"7","author":"RJ Gilbertson","year":"2007","unstructured":"Gilbertson RJ, Rich JN. Making a tumour\u2019s bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer. 2007;7:733\u20136.","journal-title":"Nat Rev Cancer"},{"key":"6435_CR2","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol (Berl). 2016;131:803\u201320.","journal-title":"Acta Neuropathol (Berl)"},{"key":"6435_CR3","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1007\/s11538-012-9786-1","volume":"74","author":"A Mart\u00ednez-Gonz\u00e1lez","year":"2012","unstructured":"Mart\u00ednez-Gonz\u00e1lez A, Calvo GF, P\u00e9rez Romasanta LA, P\u00e9rez-Garc\u00eda VM. Hypoxic cell waves around necrotic cores in Glioblastoma: a biomathematical model and its therapeutic implications. Bull Math Biol. 2012;74:2875\u201396.","journal-title":"Bull Math Biol"},{"key":"6435_CR4","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987\u201396.","journal-title":"N Engl J Med"},{"key":"6435_CR5","doi-asserted-by":"publisher","first-page":"e0118201","DOI":"10.1371\/journal.pone.0118201","volume":"10","author":"K Irshad","year":"2015","unstructured":"Irshad K, Mohapatra SK, Srivastava C, Garg H, Mishra S, Dikshit B, et al. A combined gene signature of hypoxia and notch pathway in human glioblastoma and its prognostic relevance. PLoS One. 2015;10:e0118201.","journal-title":"PLoS One"},{"key":"6435_CR6","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/neuonc\/not024","volume":"15","author":"Y-W Kim","year":"2013","unstructured":"Kim Y-W, Koul D, Kim SH, Lucio-Eterovic AK, Freire PR, Yao J, et al. Identification of prognostic gene signatures of glioblastoma: a study based on TCGA data analysis. Neuro-Oncol. 2013;15:829\u201339.","journal-title":"Neuro-Oncol."},{"key":"6435_CR7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/00001622-200305000-00003","volume":"15","author":"GJ Kitange","year":"2003","unstructured":"Kitange GJ, Templeton KL, Jenkins RB. Recent advances in the molecular genetics of primary gliomas. Curr Opin Oncol. 2003;15:197\u2013203.","journal-title":"Curr Opin Oncol"},{"key":"6435_CR8","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.3892\/ijo.2014.2358","volume":"44","author":"F Marampon","year":"2014","unstructured":"Marampon F, Gravina GL, Zani BM, Popov VM, Fratticci A, Cerasani M, et al. Hypoxia sustains glioblastoma radioresistance through ERKs\/DNA-PKcs\/HIF-1\u03b1 functional interplay. Int J Oncol. 2014;44:2121\u201331.","journal-title":"Int J Oncol"},{"key":"6435_CR9","doi-asserted-by":"publisher","first-page":"69173","DOI":"10.18632\/oncotarget.12507","volume":"7","author":"AL Rinkenbaugh","year":"2016","unstructured":"Rinkenbaugh AL, Cogswell PC, Calamini B, Dunn DE, Persson AI, Weiss WA, et al. IKK\/NF-\u03baB signaling contributes to glioblastoma stem cell maintenance. Oncotarget. 2016;7:69173\u201387.","journal-title":"Oncotarget."},{"key":"6435_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11060-007-9390-7","volume":"85","author":"B Raychaudhuri","year":"2007","unstructured":"Raychaudhuri B, Han Y, Lu T, Vogelbaum MA. Aberrant constitutive activation of nuclear factor kappaB in glioblastoma multiforme drives invasive phenotype. J Neuro-Oncol. 2007;85:39\u201347.","journal-title":"J Neuro-Oncol"},{"key":"6435_CR11","doi-asserted-by":"publisher","first-page":"e1501292","DOI":"10.1126\/sciadv.1501292","volume":"2","author":"D Friedmann-Morvinski","year":"2016","unstructured":"Friedmann-Morvinski D, Narasimamurthy R, Xia Y, Myskiw C, Soda Y, Verma IM. Targeting NF-\u03baB in glioblastoma: a therapeutic approach. Sci Adv. 2016;2:e1501292.","journal-title":"Sci Adv"},{"key":"6435_CR12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/neuonc\/nov265","volume":"18","author":"KE Cahill","year":"2016","unstructured":"Cahill KE, Morshed RA, Yamini B. Nuclear factor-\u03baB in glioblastoma: insights into regulators and targeted therapy. Neuro-Oncol. 2016;18:329\u201339.","journal-title":"Neuro-Oncol."},{"key":"6435_CR13","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3171\/jns.2002.96.5.0909","volume":"96","author":"S Nagai","year":"2002","unstructured":"Nagai S, Washiyama K, Kurimoto M, Takaku A, Endo S, Kumanishi T. Aberrant nuclear factor-kappaB activity and its participation in the growth of human malignant astrocytoma. J Neurosurg. 2002;96:909\u201317.","journal-title":"J Neurosurg"},{"key":"6435_CR14","doi-asserted-by":"publisher","first-page":"646","DOI":"10.18632\/oncotarget.322","volume":"2","author":"L Nogueira","year":"2011","unstructured":"Nogueira L, Ruiz-Onta\u00f1on P, Vazquez-Barquero A, Moris F, Fernandez-Luna JL. The NF\u03baB pathway: a therapeutic target in glioblastoma. Oncotarget. 2011;2:646\u201353.","journal-title":"Oncotarget."},{"key":"6435_CR15","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/ar2575","volume":"11","author":"KM Oliver","year":"2009","unstructured":"Oliver KM, Taylor CT, Cummins EP. Hypoxia. Regulation of NF\u03baB signalling during inflammation: the role of hydroxylases. Arthritis Res Ther. 2009;11:215.","journal-title":"Arthritis Res Ther"},{"key":"6435_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1742-2094-8-32","volume":"8","author":"M Tafani","year":"2011","unstructured":"Tafani M, Di Vito M, Frati A, Pellegrini L, De Santis E, Sette G, et al. Pro-inflammatory gene expression in solid glioblastoma microenvironment and in hypoxic stem cells from human glioblastoma. J Neuroinflammation. 2011;8:32.","journal-title":"J Neuroinflammation"},{"key":"6435_CR17","doi-asserted-by":"publisher","first-page":"3798","DOI":"10.1038\/onc.2012.393","volume":"32","author":"B Dikshit","year":"2013","unstructured":"Dikshit B, Irshad K, Madan E, Aggarwal N, Sarkar C, Chandra PS, et al. FAT1 acts as an upstream regulator of oncogenic and inflammatory pathways, via PDCD4, in glioma cells. Oncogene. 2013;32:3798\u2013808.","journal-title":"Oncogene."},{"key":"6435_CR18","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1002\/ijc.30386","volume":"139","author":"E Madan","year":"2016","unstructured":"Madan E, Dikshit B, Gowda SH, Srivastava C, Sarkar C, Chattopadhyay P, et al. FAT1 is a novel upstream regulator of HIF1\u03b1 and invasion of high grade glioma. Int J Cancer. 2016;139:2570\u201382.","journal-title":"Int J Cancer"},{"issue":"4","key":"6435_CR19","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1002\/ijc.31092","volume":"142","author":"C Srivastava","year":"2017","unstructured":"Srivastava C, Irshad K, Dikshit B, Chattopadhyay P, Sarkar C, Gupta DK, et al. FAT1 modulates EMT and stemness genes expression in hypoxic glioblastoma. Int J Cancer. 2017;142(4):805\u201312.","journal-title":"Int J Cancer"},{"key":"6435_CR20","first-page":"2781","volume":"142","author":"C Badouel","year":"2015","unstructured":"Badouel C, Zander MA, Liscio N, Bagherie-Lachidan M, Sopko R, Coyaud E, et al. Fat1 interacts with Fat4 to regulate neural tube closure, neural progenitor proliferation and apical constriction during mouse brain development. Dev Camb Engl. 2015;142:2781\u201391.","journal-title":"Dev Camb Engl"},{"key":"6435_CR21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1006\/geno.1995.9884","volume":"30","author":"J Dunne","year":"1995","unstructured":"Dunne J, Hanby AM, Poulsom R, Jones TA, Sheer D, Chin WG, et al. Molecular cloning and tissue expression of FAT, the human homologue of the Drosophila fat gene that is located on chromosome 4q34-q35 and encodes a putative adhesion molecule. Genomics. 1995;30:207\u201323.","journal-title":"Genomics."},{"key":"6435_CR22","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1083\/jcb.200403006","volume":"165","author":"T Tanoue","year":"2004","unstructured":"Tanoue T, Takeichi M. Mammalian Fat1 cadherin regulates actin dynamics and cell\u2013cell contact. J Cell Biol. 2004;165:517\u201328.","journal-title":"J Cell Biol"},{"key":"6435_CR23","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1038\/leu.2011.319","volume":"26","author":"CE de Bock","year":"2012","unstructured":"de Bock CE, Ardjmand A, Molloy TJ, Bone SM, Johnstone D, Campbell DM, et al. The Fat1 cadherin is overexpressed and an independent prognostic factor for survival in paired diagnosis-relapse samples of precursor B-cell acute lymphoblastic leukemia. Leukemia. 2012;26:918\u201326.","journal-title":"Leukemia."},{"key":"6435_CR24","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/bjc.2016.145","volume":"115","author":"P Pileri","year":"2016","unstructured":"Pileri P, Campagnoli S, Grandi A, Parri M, De Camilli E, Song C, et al. FAT1: a potential target for monoclonal antibody therapy in colon cancer. Br J Cancer. 2016;115:40\u201351.","journal-title":"Br J Cancer"},{"key":"6435_CR25","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1093\/carcin\/bgu054","volume":"35","author":"D Valletta","year":"2014","unstructured":"Valletta D, Czech B, Spruss T, Ikenberg K, Wild P, Hartmann A, et al. Regulation and function of the atypical cadherin FAT1 in hepatocellular carcinoma. Carcinogenesis. 2014;35:1407\u201315.","journal-title":"Carcinogenesis."},{"key":"6435_CR26","doi-asserted-by":"publisher","first-page":"e90461","DOI":"10.1371\/journal.pone.0090461","volume":"9","author":"N Wojtalewicz","year":"2014","unstructured":"Wojtalewicz N, Sadeqzadeh E, Wei\u00df JV, Tehrani MM, Klein-Scory S, Hahn S, et al. A soluble form of the giant cadherin Fat1 is released from pancreatic cancer cells by ADAM10 mediated ectodomain shedding. PLoS One. 2014;9:e90461.","journal-title":"PLoS One"},{"key":"6435_CR27","first-page":"587","volume":"26","author":"Y Nishikawa","year":"2011","unstructured":"Nishikawa Y, Miyazaki T, Nakashiro K-I, Yamagata H, Isokane M, Goda H, et al. Human FAT1 cadherin controls cell migration and invasion of oral squamous cell carcinoma through the localization of \u03b2-catenin. Oncol Rep. 2011;26:587\u201392.","journal-title":"Oncol Rep"},{"key":"6435_CR28","first-page":"1013","volume":"165","author":"NS Chandel","year":"2000","unstructured":"Chandel NS, Trzyna WC, McClintock DS, Schumacker PT. Role of oxidants in NF-kappa B activation and TNF-alpha gene transcription induced by hypoxia and endotoxin. J Immunol Baltim Md 1950. 2000;165:1013\u201321.","journal-title":"J Immunol Baltim Md 1950"},{"issue":"6 Pt 1","key":"6435_CR29","first-page":"L909","volume":"276","author":"SK Leeper-Woodford","year":"1999","unstructured":"Leeper-Woodford SK, Detmer K. Acute hypoxia increases alveolar macrophage tumor necrosis factor activity and alters NF-kappaB expression. Am J Phys. 1999;276(6 Pt 1):L909\u201316.","journal-title":"Am J Phys"},{"key":"6435_CR30","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1158\/2326-6066.CIR-14-0112","volume":"2","author":"Y Xia","year":"2014","unstructured":"Xia Y, Shen S, Verma IM. NF-\u03baB, an active player in human cancers. Cancer Immunol Res. 2014;2:823\u201330.","journal-title":"Cancer Immunol Res"},{"key":"6435_CR31","first-page":"181","volume":"33","author":"D Kranz","year":"2014","unstructured":"Kranz D, Boutros M. A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis. EMBO J. 2014;33:181\u201397.","journal-title":"EMBO J"},{"key":"6435_CR32","doi-asserted-by":"crossref","first-page":"98887","DOI":"10.18632\/oncotarget.21946","volume":"8","author":"M-H Kang","year":"2017","unstructured":"Kang M-H, Jeong GS, Smoot DT, Ashktorab H, Hwang CM, Kim BS, et al. Verteporfin inhibits gastric cancer cell growth by suppressing adhesion molecule FAT1. Oncotarget. 2017;8:98887\u201397.","journal-title":"Oncotarget."},{"key":"6435_CR33","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.1128\/MCB.00409-10","volume":"30","author":"C Culver","year":"2010","unstructured":"Culver C, Sundqvist A, Mudie S, Melvin A, Xirodimas D, Rocha S. Mechanism of hypoxia-induced NF-\u03baB. Mol Cell Biol. 2010;30:4901\u201321.","journal-title":"Mol Cell Biol"},{"key":"6435_CR34","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/0012-1606(88)90399-5","volume":"129","author":"PJ Bryant","year":"1988","unstructured":"Bryant PJ, Huettner B, Held LI, Ryerse J, Szidonya J. Mutations at the fat locus interfere with cell proliferation control and epithelial morphogenesis in Drosophila. Dev Biol. 1988;129:541\u201354.","journal-title":"Dev Biol"},{"key":"6435_CR35","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1083\/jcb.200508121","volume":"173","author":"R Hou","year":"2006","unstructured":"Hou R, Liu L, Anees S, Hiroyasu S, Sibinga NES. The Fat1 cadherin integrates vascular smooth muscle cell growth and migration signals. J Cell Biol. 2006;173:417\u201329.","journal-title":"J Cell Biol"},{"key":"6435_CR36","doi-asserted-by":"publisher","first-page":"3769","DOI":"10.1038\/sj.emboj.7600380","volume":"23","author":"MJ Moeller","year":"2004","unstructured":"Moeller MJ, Soofi A, Braun GS, Li X, Watzl C, Kriz W, et al. Protocadherin FAT1 binds Ena\/VASP proteins and is necessary for actin dynamics and cell polarization. EMBO J. 2004;23:3769\u201379.","journal-title":"EMBO J"},{"key":"6435_CR37","doi-asserted-by":"publisher","first-page":"5295","DOI":"10.1016\/j.febslet.2006.08.079","volume":"580","author":"D Schreiner","year":"2006","unstructured":"Schreiner D, M\u00fcller K, Hofer HW. The intracellular domain of the human protocadherin hFat1 interacts with Homer signalling scaffolding proteins. FEBS Lett. 2006;580:5295\u2013300.","journal-title":"FEBS Lett"},{"key":"6435_CR38","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/ng.2538","volume":"45","author":"LGT Morris","year":"2013","unstructured":"Morris LGT, Kaufman AM, Gong Y, Ramaswami D, Walsh LA, Turcan \u015e, et al. Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nat Genet. 2013;45:253\u201361.","journal-title":"Nat Genet"},{"key":"6435_CR39","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nri1703","volume":"5","author":"M Karin","year":"2005","unstructured":"Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5:749\u201359.","journal-title":"Nat Rev Immunol"},{"key":"6435_CR40","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1182\/blood-2005-02-0759","volume":"106","author":"H Qin","year":"2005","unstructured":"Qin H, Wilson CA, Lee SJ, Zhao X, Benveniste EN. LPS induces CD40 gene expression through the activation of NF-kappaB and STAT-1alpha in macrophages and microglia. Blood. 2005;106:3114\u201322.","journal-title":"Blood."},{"key":"6435_CR41","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.drudis.2011.09.003","volume":"16","author":"E Sen","year":"2011","unstructured":"Sen E. Targeting inflammation-induced transcription factor activation: an open frontier for glioma therapy. Drug Discov Today. 2011;16:1044\u201351.","journal-title":"Drug Discov Today"},{"key":"6435_CR42","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1056\/NEJMoa1006312","volume":"364","author":"M Bredel","year":"2011","unstructured":"Bredel M, Scholtens DM, Yadav AK, Alvarez AA, Renfrow JJ, Chandler JP, et al. NFKBIA deletion in glioblastomas. N Engl J Med. 2011;364:627\u201337.","journal-title":"N Engl J Med"},{"key":"6435_CR43","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/nature06905","volume":"453","author":"J Rius","year":"2008","unstructured":"Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, Nizet V, et al. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature. 2008;453:807\u201311.","journal-title":"Nature."},{"key":"6435_CR44","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1042\/BJ20080476","volume":"412","author":"P van Uden","year":"2008","unstructured":"van Uden P, Kenneth NS, Rocha S. Regulation of hypoxia-inducible factor-1alpha by NF-kappaB. Biochem J. 2008;412:477\u201384.","journal-title":"Biochem J"},{"key":"6435_CR45","doi-asserted-by":"publisher","first-page":"26167","DOI":"10.1074\/jbc.M113.477950","volume":"288","author":"JM Garner","year":"2013","unstructured":"Garner JM, Fan M, Yang CH, Du Z, Sims M, Davidoff AM, et al. Constitutive activation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor \u03baB signaling in glioblastoma cancer stem cells regulates the notch pathway. J Biol Chem. 2013;288:26167\u201376.","journal-title":"J Biol Chem"},{"key":"6435_CR46","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/ncomms1159","volume":"2","author":"VK Rajasekhar","year":"2011","unstructured":"Rajasekhar VK, Studer L, Gerald W, Socci ND, Scher HI. Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-\u03baB signalling. Nat Commun. 2011;2:162.","journal-title":"Nat Commun"},{"key":"6435_CR47","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1002\/stem.188","volume":"27","author":"H Wang","year":"2009","unstructured":"Wang H, Lathia JD, Wu Q, Wang J, Li Z, Heddleston JM, et al. Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells Dayt Ohio. 2009;27:2393\u2013404.","journal-title":"Stem Cells Dayt Ohio"},{"key":"6435_CR48","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.tips.2012.01.005","volume":"33","author":"GL Semenza","year":"2012","unstructured":"Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci. 2012;33:207\u201314.","journal-title":"Trends Pharmacol Sci"},{"key":"6435_CR49","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejmech.2012.01.033","volume":"49","author":"Y Xia","year":"2012","unstructured":"Xia Y, Choi H-K, Lee K. Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. Eur J Med Chem. 2012;49:24\u201340.","journal-title":"Eur J Med Chem"},{"key":"6435_CR50","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1517\/14728220903431069","volume":"14","author":"Y Lin","year":"2010","unstructured":"Lin Y, Bai L, Chen W, Xu S. The NF-\u03baB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin Ther Targets. 2010;14:45\u201355.","journal-title":"Expert Opin Ther Targets"},{"key":"6435_CR51","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s10495-009-0315-0","volume":"14","author":"H-M Shen","year":"2009","unstructured":"Shen H-M, Tergaonkar V. NFkappaB signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis Int J Program Cell Death. 2009;14:348\u201363.","journal-title":"Apoptosis Int J Program Cell Death"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6435-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-6435-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6435-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T19:06:54Z","timestamp":1611688014000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-6435-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,28]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["6435"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-6435-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,28]]},"assertion":[{"value":"4 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"\u2022Surgically resected human GBM samples were collected with due patient written consent after approval by Institute Ethics-Committee, AIIMS, New Delhi (Ref. No IESC\/T-416\/01.11.2013).\u2022ATCC cell lines used in this study have been authenticated by STR cell identification (Project ID: M-1070, Lifecode, New Delhi) on 12th, July, 2016. Cell lines were not infected by mycoplasma.\u2022Approval for use of the cell lines for in-vitro study was received from Institutional Committee on Bio-safety for Recombinant DNA Research, AIIMS, New Delhi, dated 6th April 2015.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}